CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 32 enrolled
Drug / intervention
PM060184drug
Likely dose
PM060184 9.3 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03427268
NCT03427268Phase 2Completed
CompareCT.gov

A Phase II, Open-label, Multicentre Study of PM060184 in Patients With Advanced Colorectal Cancer After Standard Treatment.

PharmaMar·interventional·Posted Feb 9, 2018·Updated May 24, 2021

In Brief

A Phase 2 clinical trial evaluating PM060184 for Advanced Colorectal Cancer. Completed, enrolled 32 participants across 5 sites in 3 countries.

Detailed Summary

This trial will evaluate the efficacy of PM060184 in terms of progression-free survival at 12 weeks (PFS3) in advanced or metastatic Colorectal Cancer (CRC) patients with any KRAS mutation status (wild- type; mutated; or unknown status) progressing after standard treatments (fluoropyrimidine, irinotecan, and oxaliplatin). Patients in this trial will receive PM060184 at a dose of 9.3 mg/m2 as a 30-minute intravenous (i.v.) infusion on Days 1 and 8 q3wk.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Colorectal Cancer
CountriesCanada, Spain, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 9, 2018
Enrollment StartJan 16, 2018
Primary CompletionFeb 11, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.4 years ago

Interventions

PM060184drug

PM060184: 9.3 mg/m2 PM060184 i.v. as a 30-minute infusion via a central or peripheral venous catheter.Dose can be rounded to the first decimal point. PM060184 will be administered on Day 1 and Day 8 q3wk. (Three weeks=one treatment cycle).